Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies
about
Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.The significance of FOXP1 in diffuse large B-cell lymphoma.Molecular subtype classification of formalin-fixed, paraffin-embedded diffuse large B-cell lymphoma samples on the ICEPlex® system.Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithmsPellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination.Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOPDiffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosisEpstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.Lectin-like transcript 1 is a marker of germinal center-derived B-cell non-Hodgkin's lymphomas dampening natural killer cell functionsFrontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review.The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.Machine learning-based classification of diffuse large B-cell lymphoma patients by eight gene expression profiles.The prognosis of MYC translocation positive diffuse large B-cell lymphoma depends on the second hit.Cross-platform assessment of genomic imbalance confirms the clinical relevance of genomic complexity and reveals loci with potential pathogenic roles in diffuse large B-cell lymphoma.Multiplex sequencing for EZH2, CD79B, and MYD88 mutations using archival cytospin preparations from B-cell non-Hodgkin lymphoma aspirates previously tested for MYC rearrangement and IGH/BCL2 translocation.Molecular Classification of Tumor Cells in a Patient with Intravascular Large B-Cell Lymphoma.Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?Serum nuclear magnetic resonance-based metabolomics and outcome in diffuse large B-cell lymphoma patients - a pilot study.Diffuse large B-cell lymphoma: sub-classification by massive parallel quantitative RT-PCR.Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.Molecular Subtypes, Apoptosis and Proliferation Status in Indonesian Diffuse Large B-Cell Lymphoma CasesRefining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma.Cell of origin predicts outcome to treatment with etoposide-containing chemotherapy in young patients with high-risk diffuse large B-cell lymphoma.Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma.Pathology and classification of aggressive mature B-cell lymphomas.
P2860
Q27027137-DA4B4F9A-D6AF-4DA4-993A-7658883EB100Q33591789-3DC9D85B-C15A-4B14-9A7E-75826C3218ADQ33846801-B9255BD3-74EE-4C17-A3A9-CA44D6738702Q34047455-B2231CD7-DB5D-4EDE-8C97-CC2D33DB0B9EQ34302170-2EFF8999-0BD0-4B7F-9EA4-50FBE6BC69A1Q34617849-9D90E3A4-3930-4904-83B5-234BE577D8CBQ35140039-17EC225C-7D4F-4191-ABC0-5A46C0247D66Q35145270-AA5C0A5D-8918-484F-9DC1-857506FA6378Q35419876-7A31DB4E-3419-429F-B00F-F43A1F92D3FEQ35880791-10131C9C-6659-4617-A345-69FCB90B557DQ36060329-8F078963-B661-4F5E-A388-5EF2944D582BQ36192439-340F6E93-6C72-4EEA-BE90-83773AB635FBQ36302961-88D1ABF4-A0CF-4CF1-9A0B-43F1D672E386Q36559885-39F9EE03-F2EB-48D3-92EB-46B9EC99F07DQ36895068-C0719813-EEBF-4051-8F9D-247BAED15D6AQ37024999-92DCF6B2-7C82-4817-BC50-587CC083E960Q37132882-C54D6958-DDAF-4F66-B9D7-2EAF9653240FQ38387178-4EF8E07F-485B-4833-93FA-7CA2F789BF4FQ38653398-67CF43C4-C87F-412F-927B-B0CCC8B4CE9DQ38656983-70D46950-8B30-4376-A1A6-D58D81F49D59Q38812004-6C046110-879C-46BA-9A07-DA515A337798Q38959472-470C871B-291B-43E1-AA2D-833CA8924F95Q39324849-7B49A3F0-A919-4A71-B767-075A8142D89CQ39628753-43135F3E-4C5C-4A5C-959B-5F873993C870Q39989686-AC69A73C-7215-4790-B939-763AD3ECBA6EQ43611099-83BFAC2E-7781-40BE-A779-78874F4E6AA0Q48338600-BE3B6CBD-024B-4478-9D33-2DC5EFA42F2DQ49648511-0266117F-1AB5-45D7-A2DB-49F429B908EFQ50211895-69EE6151-BBF7-488E-BD2C-24698B548E87Q51014998-5638AECA-2E92-4DC9-A6A8-CAF12D6D3D41Q53505510-186C2880-1ABE-4F99-9928-A39875620DF4Q53606604-6EAFB1E7-3520-4E94-A9FB-9BCCE77AA8D2Q53837958-FBFBA33F-FB2D-47C6-9965-AA7B018060ED
P2860
Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Poor concordance among nine im ...... ons for therapeutic strategies
@ast
Poor concordance among nine im ...... ons for therapeutic strategies
@en
Poor concordance among nine im ...... ons for therapeutic strategies
@nl
type
label
Poor concordance among nine im ...... ons for therapeutic strategies
@ast
Poor concordance among nine im ...... ons for therapeutic strategies
@en
Poor concordance among nine im ...... ons for therapeutic strategies
@nl
prefLabel
Poor concordance among nine im ...... ons for therapeutic strategies
@ast
Poor concordance among nine im ...... ons for therapeutic strategies
@en
Poor concordance among nine im ...... ons for therapeutic strategies
@nl
P2093
P2860
P1476
Poor concordance among nine im ...... ons for therapeutic strategies
@en
P2093
Abigail Lee
Andrew James Clear
Andrew Owen
Andrew Wilson
Janet Matthews
John G Gribben
Maria Calaminici
Rita Coutinho
Rute Alvarez
P2860
P304
P356
10.1158/1078-0432.CCR-13-1482
P407
P577
2013-10-11T00:00:00Z